HMS5552 is an investigational drug.
There have been 13 clinical trials for HMS5552.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 15th 2017.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and [disabled in preview]. The leading clinical trial sponsors are Hua Medicine Limited, Tigermed Consulting Co., Ltd, and Covance.
There are two US patents protecting this investigational drug and fifty-two international patents.